Search Results
Your search for ,maY matches 16750 pages
Showing 7901 - 7950Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers
Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...
Study Finds New Candidate Susceptibility Genes for High-Grade Serous Ovarian Cancer
A team of researchers have identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer. The findings, published by Gusev et al in Nature Genetics, may help identify women who are at highest risk of developing ovarian cancer and pave the way...
HPV DNA and Outcomes After Primary Treatment for Oral and Oropharyngeal Squamous Cell Carcinomas
In a two-institution study reported in JAMA Oncology, Fakhry et al found that persistent detection of tumor-type human papillomavirus (HPV) DNA after primary treatment for oral and oropharyngeal squamous cell carcinomas was associated with poorer outcomes. Study Details The prospective study...
Sentinel Lymph Node Biopsy With or Without Use of Preoperative Lymphoscintigraphy in Early Breast Cancer
In a German/Swiss phase III trial (SenSzi [GBG80]) reported in the Journal of Clinical Oncology, Kuemmel et al found that preoperative lymphoscintigraphy was not associated with an increased number of histologically detected sentinel lymph nodes with sentinel lymph node biopsy in women with early...
ARRS 2019: Arterial-Phase Hyperenhancement for Hepatocellular Carcinoma Treated With SBRT
Although arterial-phase hyperenhancement is a key feature of untreated or recurrent hepatocellular carcinoma, standard response assessment such as modified Response Evaluation Criteria in Solid Tumors (mRECIST) should be used with caution, particularly in the early phases after stereotactic body...
Addition of Decitabine to Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Nie et al found a higher complete response rate with the addition of low-dose decitabine to the programmed cell death protein 1 (PD-1) inhibitor camrelizumab in anti–PD-1 treatment–naive patients with...
FDA Approves Ramucirumab for Hepatocellular Carcinoma
On May 10, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza) as a single agent for hepatocellular carcinoma in patients who have an alpha-fetoprotein (AFP) level ≥ 400 ng/mL and have been previously treated with sorafenib. REACH-2 Trial Approval was based on the...
For Your Patients: New ASCO Answers Fact Sheet on Immunotherapy Side Effects
IMMUNOTHERAPY IS changing the way that cancer is being treated, but the understanding of the side effects of these treatments is still a developing field. The ASCO Answers “Side Effects of Immunotherapy” fact sheet helps patients learn about which side effects may arise from treatment with...
Third Brazilian Practice Achieves QOPI® Certification
ACREDITAR ONCOLOGY has become the 3rd practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC, and the 10th practice internationally to receive this accreditation. The practice, located in Brasília’s Federal District,...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
NOT EVERY ONCOLOGIST grows up dreaming of becoming a doctor. In the Your Stories podcast episode “The Forest Ranger in a White Coat,” once-reluctant physician Stuart Spigel, MD, shares how becoming a patient changed his approach to practicing medicine with his son and fellow oncologist David...
ASCO Launches FY 2020 Advocacy Campaign for Federally Funded Cancer Research
ASCO HAS KICKED OFF its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH)—a $2.5 billion increase from FY 2019— and $6.5 billion to the National Cancer...
Enhance Your 2019 ASCO Annual Meeting Experience at Podcast Listening Station
THE ASCO ANNUAL Meeting is 5 bustling days of cutting-edge research presentations, educational sessions, and networking events. To enhance conference takeaways and connect attendees more closely with content from the 2019 Annual Meeting, ASCO will host a podcast listening station onsite at...
Conquer Cancer and Swim Across America: Making Waves to Fight Cancer
ASCO and ASCO’s Conquer Cancer Foundation have a new partner in supporting innovative cancer research. For over 30 years, Swim Across America (SAA) has been hosting charity swims, with the proceeds being granted to fund high-risk, high-reward cancer research. SAA is among the newest organizations...
CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain
ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) recently acknowledged receipt of a key clarification1 from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification...
Study Finds Immune Enrichment Improves Outcomes in Pancreatic Cancer With Activated but Not Normal Stroma
ALTHOUGH IMMUNOTHERAPIES have had limited success in pancreatic cancer to date, findings from a molecular analysis of the tumor microenvironment suggest that certain subtypes may be more responsive to treatment. According to data presented at the 2019 Society of Surgical Oncology Annual Cancer...
FDA Advances Policy Changes to Modernize Mammography Services
ON MARCH 27, 2019, the U.S. Food and Drug Administration (FDA) announced important new steps to modernize breast cancer screening and help empower patients with more information when they are considering important decisions regarding their breast health care. For the first time in more than 20...
Postprogression Treatment of Estrogen Receptor–Positive Breast Cancer: Future Approaches
AT THE 2019 Miami Breast Cancer Conference, William J. Gradishar, MD, FASCO, presented a vision of the future in the treatment of advanced hormone receptor–positive breast cancer.1 The refinement of disease subsets, the development of agents targeting the PI3K/AKT/mTOR pathway, the use of novel...
Emil J Freireich, MD, FAACR, Honored With AACR Award for Lifetime Achievement in Cancer Research
THE AMERICAN Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR Award for Lifetime Achievement in Cancer Research at the opening ceremony of this year’s AACR Annual Meeting. Dr. Freireich was honored for his work in establishing combination...
Pembrolizumab as Third-Line Option for Extensive-Stage Small Cell Lung Cancer
USE OF the anti–programmed cell death protein 1 (anti–PD-1) checkpoint inhibitor pembrolizumab after two or more prior lines of therapy led to responses in patients with advanced small cell lung cancer (SCLC) in a pooled analysis of two clinical trials: phase Ib KEYNOTE-028 and phase II...
AACR Study Presentations Include New Data in Breast and Prostate Cancers, Sarcoma, and High-Risk Individuals
THE 2019 American Association for Cancer Research (AACR) Annual Meeting was held March 29 to April 3 in Atlanta. In addition to our regular coverage of news stories from the meeting, here are some brief highlights of additional noteworthy studies. Stage IV HER2-Positive Breast Cancer: Surgery or No ...
Expert Point of View: Louis M. Weiner, MD, and Thomas Habermann, MD
“THIS REPRESENTS the fruits of years of research. Umbralisib is a more potent and selective PI3K inhibitor targeted to the delta isoform. This provides a more precise target for drugs that block that protein, and it more effectively disables signaling. The B cell is central to the survival of...
Umbralisib: Potential Option for Relapsed or Refractory Marginal Zone Lymphoma
UMBRALISIB—an investigational PI3K-delta inhibitor—produced impressive results as monotherapy in patients with relapsed or refractory marginal zone lymphoma, according to an interim analysis of the phase II UNITY-NHL trial presented at the 2019 American Association for Cancer Research (AACR) Annual ...
Expert Point of View: Namrata Vijayvergia, MD
NAMRATA VIJAYVERGIA, MD, of Fox Chase Cancer Center, Philadelphia, commented on this study. “This is an important study because it is done in a rare tumor type; not a lot of clinical trials are conducted in this disease. Recently, three other studies of single-agent therapy with checkpoint...
Dual-Immunotherapy Approach Shows Efficacy in High-Grade Neuroendocrine Tumors
COMBINING TWO established immunotherapy agents achieved tumor shrinkage in rare, aggressive, extrapancreatic high-grade neuroendocrine tumors, according to the results of SWOG S1609, a phase II clinical basket trial also known as DART (Dual Anti– CLTA-4 and Anti–PD-1 Blockade in Rare Tumors). The...
Expert Point of View: Roy S. Herbst, MD, PhD
FORMAL STUDY discussant, Roy S. Herbst, MD, PhD, Chief of Medical Oncology at the Yale Cancer Center, New Haven, Connecticut, stated that the findings of the TATTON analyses are “compelling,” and the combination of osimertinib plus savolitinib can be considered a “win,” although randomized trials...
Osimertinib Plus Savolitinib in Advanced NSCLC Driven by MET Resistance
THE ADDITION of the MET inhibitor savolitinib to the EGFR inhibitor osimertinib led to activity in patients with MET-amplified, EGFR-mutated non–small lung cancer (NSCLC) with acquired resistance to previous therapies, according to interim results from two expansion cohorts of a phase Ib clinical...
Front-Line Therapy in Advanced Renal Cell Carcinoma: Developing a New Standard
THE FRONT-LINE systemic treatment landscape for metastatic renal cell carcinoma has undergone tremendous movement over the past several years. A better understanding of the current management paradigm for therapy-naive patients warrants a reflection of historic landmark clinical trials that have...
Harnessing the Power of Twitter for Clinical Trial Enrollment and Success
CLINICAL TRIALS are vital for advancing cancer care for our patients. Each trial represents an unanswered problem for which researchers are committed to solving. Designing, funding, recruiting, and completing a trial are tremendous undertakings for each researcher, physician, patient, and...
Neoadjuvant Immunotherapy Associated With Improved Outcomes in Patients With Locally Advanced Melanoma
ACCORDING TO DATA from a small prospective study presented at the 2019 Society of Surgical Oncology Annual Cancer Symposium,1 neoadjuvant immunotherapy significantly prolonged relapse-free survival vs adjuvant immunotherapy in patients with stage III or oligometastatic stage IV melanoma intended...
FDA Pipeline: Designations in Triple-Negative Breast Cancer, ctDNA Detection
This week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for CCR5-positive metastatic triple-negative breast cancer; granted Breakthrough Device designation to a test for the postsurgical detection and quantification of circulating tumor DNA (ctDNA);...
IMPACT Study, Aimed at Increasing Diversity Among Clinical Trial Participants, Launches
The University of Southern California (USC) Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities....
Oropharyngeal Cancer Trends in White Men
In a study reported in the Journal of Clinical Oncology, Tota et al found that there has been a reduction in the increase of oropharyngeal cancer among young white men, with a high number of cases projected among older white men in coming years. As stated by the investigators, “Human...
WINTHER Trial: Genomic and Transcriptomic Profiling May Translate to New Therapeutic Options for Patients With Advanced Cancer
Published by Rodon et al in Nature Medicine, results of the WINTHER study showed that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial aimed to...
ASBrS 2019: Comprehensive Postoperative Mastectomy Home Recovery Programs Show Patient Benefit
Comprehensive postoperative mastectomy home recovery programs significantly increased same-day patient discharge with no decrease in quality of care, according to two new studies presented at the Annual Meeting of the American Society of Breast Surgeons (ASBrS). “Research demonstrates the...
Impact of Consensus Molecular Subtype on Outcome in Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Innocenti et al found that consensus molecular subtype of colorectal cancers was highly prognostic for outcomes in patients receiving first-line treatment for advanced disease in the phase III CALGB/SWOG 80405/Alliance trial. CALGB/SWOG...
AUA 2019: Studies Highlight Potential Bladder Cancer Risks
Electronic cigarettes (e-cigarettes), exposure to certain environmental factors, and human papillomavirus (HPV) infection may increase the risk of developing bladder cancer, according to new data presented this week at the 2019 Annual Meeting of the American Urological Association (AUA). The...
AUA 2019: Insights in Prostate Cancer Identification and Management
Prostate cancer diagnosis and treatment are ever-changing, with new research showcasing different ways to identify and manage patients with the disease. Three new abstracts—highlighting how beta-blockers may impact prostate cancer risk, the advantages and disadvantages of using magnetic...
ASBrS 2019: Bioimpedance Spectroscopy for Surveillance of Breast Cancer–Related Lymphedema
Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy. These were the results of an...
ASBrS 2019: Factors Associated With Nonoperative Management of Select Patients With HER2-Positive Breast Cancer
Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively....
FDA Approves Ado-Trastuzumab Emtansine for HER2-Positive Early Breast Cancer
On May 3, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane- and trastuzumab-based treatment. Patients should be...
ESTRO 38: REQUITE Project Finds Predictive Biomarkers for Late Radiotherapy Toxicity
The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse effects after radiotherapy, have shown that a combination of biologic markers and certain genetic changes can predict radiation sensitivity. In addition, the international team ...
ESTRO 38: What Type of Radiotherapy May Best Preserve Cognitive Function in Pediatric Patients With Brain Tumors?
A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam scanning (PBS) offers the best hope of preserving cognitive functions. The study, presented by Toussaint et al at ESTRO 38, the annual congress of the European Society...
FDA Pipeline: Applications and Designations in Prostate Cancer, Leukemia, and HER2-Positive Cancers
In the past 2 weeks, the U.S. Food and Drug Administration (FDA) accepted a new drug application and granted Priority Review for a prostate cancer treatment, granted Orphan Drug designation to a treatment for acute lymphoblastic leukemia, accepted an investigational new drug application for a...
FDA Approves First-Line Ivosidenib for IDH1-Mutated AML
On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...
ESTRO 38: Radiotherapy After ABVD May Improve Survival in Advanced Hodgkin Lymphoma
Patients with advanced Hodgkin lymphoma with bulky lesions at the time of diagnosis may benefit from radiotherapy after chemotherapy, according to late-breaking results presented by Ricardi et al at ESTRO 38, the annual congress of the European Society for Radiotherapy & Oncology...
ESTRO 38: Long-Term Results of Adjuvant Radiotherapy Plus Antihormonal Treatment in Hormone Receptor–Positive Breast Cancer
Women with early-stage, low-risk, hormone receptor–positive breast cancer may be less likely to experience disease recurrence if they have radiotherapy after surgery as well as antihormonal treatment, according to results from a trial that has followed 869 women for 10 years. These findings...
Psychosocial Care Is a Critical Component of Value-Based Oncology
The ongoing dialogue regarding health-care payment reform that attempts to incentivize high-value care by linking reimbursement to quality rather than quantity has largely ignored the ultimate consumer/buyer—the patient. Yet, in the minds of clinicians, policymakers, and the public at large,...
Adjuvant Capecitabine After Resection for Biliary Tract Cancer
In the phase III BILCAP trial reported in The Lancet Oncology, John N. Primrose, FMedSci, and colleagues found evidence that adjuvant capecitabine may improve overall survival vs observation following surgery for patients with resected biliary tract cancer. The open-label study included 447...
Risk of Cardiomyopathy in Childhood Cancer Survivors
In a study reported in JAMA Oncology, Eric J. Chow, MD, MPH, and colleagues found that daunorubicin was associated with decreased cardiomyopathy risk vs doxorubicin among pediatric cancer survivors, with epirubicin being approximately isoequivalent to doxorubicin. Risk associated with the...
Hope and Fear Are Two Constants in the Lives of Patients With Cancer
A year and a half ago, when I was 33, the thought of having a life-threatening disease was unimaginable. In hindsight, the weight loss I began experiencing in the fall of 2017 should have raised concern because I’ve always had to be mindful of my diet if I wanted to lose weight. But denial can be a ...
